


- 50. (New) The implant according to claim 49 wherein at least one of said agents includes an immediate release component and at least one of said agents includes a time-delayed component.
- 51. (New) The implant according to claim 49 wherein said growth promoting agent comprises from about 20-200 mg trenbolone acetate.
- 52. (New) The implant according to claim 51 wherein said supplemental agent comprises from about 5-50 mg tylosin tartrate.
- 53. (New) The implant according to claim 51 wherein said supplemental agent comprises from about 10-100 mg melengesterol acetate.
- 54. (New) The implant according to claim 51 wherein said growth promoting agent further comprises from about 5-50 mg estradiol benzoate.
- 55. (New) The implant according to claim 54 wherein said supplemental agent comprises from about 5-50 mg tylosin tartrate.
- 56. (New) The implant according to claim 54 wherein said supplemental agent comprises from about 10-100 mg melengesterol acetate.
- 55. (New) The implant according to claim 51 wherein said growth promoting agent further comprises from about 5-50 mg estradiol.
- 56. (New) The implant according to claim 55 wherein said supplemental agent comprises from about 5-50 mg tylosin tartrate.
- 57. (New) The implant according to claim 55 wherein said supplemental agent comprises from about 10-100 mg melengesterol acetate.
- 58. (New) The implant according to claim 49 wherein said growth promoting agent comprises from about 5-50 mg estradiol benzoate.

59. (New) The implant according to claim 58 wherein said supplemental agent comprises from about 5-50 mg tylosin tartrate.



- 61. (New) The implant according to claim 58 wherein said growth promoting agent further comprises from about 5-50 mg estradiol.
- 62. (New) The implant according to claim 49 wherein said growth promoting agent comprises from about 5-50 mg estradiol.
- 63. (New) The implant according to claim 62 wherein said supplemental agent comprises from about 5-50 mg tylosin tartrate.
- 64. (New) The implant according to claim 62 wherein said supplemental agent comprises from about 10-100 mg melengesterol acetate.

REMARKS

In response to the Final Office Action dated November 12, 2002, Applicant hereby makes the following response in conjunction with a Request for Continued Examination of this application. The application was filed on June 8, 2000 and included Claims 1-32. Claims 19-26 were divided out without prejudice on October 24, 2002, for a later divisional application, if necessary. A simultaneous election of species resulted in Claims 5-9, 13-18, and 27-32 being withdrawn from further consideration under 37 C.F.R. § 1.142(b). Claims 1-4 and 10-12 remained pending and Claims 33-48 were added by amendment. Claims 41-47 were also withdrawn by the Examiner from further consideration under 37 CFR 1.142(b) as drawn to a nonelected invention and species. The Examiner kindly granted Applicant a personal interview